We are live on ! Find out more
JAZZ icon

Jazz Pharmaceuticals

480 hedge funds and large institutions have $6.97B invested in Jazz Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 54 funds opening new positions, 183 increasing their positions, 160 reducing their positions, and 68 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more funds holding in top 10

Funds holding in top 10: 67 (+1)

14% more repeat investments, than reductions

Existing positions increased: 183 | Existing positions reduced: 160

0.86% more ownership

Funds ownership: 92%92.86% (+0.86%)

2% less capital invested

Capital invested by funds: $7.12B → $6.97B (-$152M)

4% less funds holding

Funds holding: 499480 (-19)

18% less call options, than puts

Call options by funds: $19.5M | Put options by funds: $23.9M

21% less first-time investments, than exits

New positions opened: 54 | Existing positions closed: 68

Holders
480
Holders Change
-19
Holders Change %
-3.81%
% of All Funds
6.91%
Holding in Top 10
7
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+16.67%
% of All Funds
0.1%
New
54
Increased
183
Reduced
160
Closed
68
Calls
$19.5M
Puts
$23.9M
Net Calls
-$4.39M
Net Calls Change
-$11.9M
Name Holding Trade Value Shares
Change
Change in
Stake
BA
76
Bridgewater Associates
Connecticut
$13.2M +$2.37M +19,375 +21%
Stifel Financial
77
Stifel Financial
Missouri
$13.2M +$7.05M +57,555 +111%
AllianceBernstein
78
AllianceBernstein
Tennessee
$12.7M -$181K -1,479 -1%
California State Teachers Retirement System (CalSTRS)
79
California State Teachers Retirement System (CalSTRS)
California
$12.3M +$389K +3,172 +3%
KAM
80
Krensavage Asset Management
New York
$12.2M +$141K +1,151 +1%
Man Group
81
Man Group
United Kingdom
$12M -$3.12M -25,461 -20%
Barclays
82
Barclays
United Kingdom
$11.8M -$1.26M -10,285 -9%
Rockefeller Capital Management
83
Rockefeller Capital Management
New York
$11.4M +$1.89M +15,413 +20%
Two Sigma Investments
84
Two Sigma Investments
New York
$11.4M +$4.89M +39,903 +73%
BSA
85
Braun Stacey Associates
New York
$11.4M -$457K -3,734 -4%
Loomis, Sayles & Company
86
Loomis, Sayles & Company
Massachusetts
$10.9M -$70.4K -575 -0.6%
Bank of Montreal
87
Bank of Montreal
Ontario, Canada
$10.8M -$865K -7,058 -7%
AIG
88
American International Group
New York
$10.1M -$210K -1,713 -2%
MPM
89
Meritage Portfolio Management
Kansas
$9.94M -$306K -2,502 -3%
Qube Research & Technologies (QRT)
90
Qube Research & Technologies (QRT)
United Kingdom
$9.45M -$35.4M -289,234 -79%
Canada Life
91
Canada Life
Manitoba, Canada
$9.42M -$293K -2,396 -3%
Mirae Asset Global Investments
92
Mirae Asset Global Investments
South Korea
$9.04M -$1.24M -10,127 -12%
BNP Paribas Financial Markets
93
BNP Paribas Financial Markets
France
$8.85M -$860K -7,024 -9%
SAM
94
Storebrand Asset Management
Norway
$8.83M +$49.4K +403 +0.6%
Mitsubishi UFJ Trust & Banking
95
Mitsubishi UFJ Trust & Banking
Japan
$8.82M +$5.14M +41,950 +132%
APG Asset Management
96
APG Asset Management
Netherlands
$8.6M +$3.75M +30,624 +66%
CAM
97
Centre Asset Management
New York
$8.47M +$8.62M +70,381 New
State Board of Administration of Florida Retirement System
98
State Board of Administration of Florida Retirement System
Florida
$8.26M +$289K +2,360 +4%
Citigroup
99
Citigroup
New York
$7.96M -$358K -2,925 -4%
Squarepoint
100
Squarepoint
New York
$7.73M -$6.36M -51,931 -45%

JAZZ Hedge Fund Activity: Q1 2024 in Review

480 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Jazz Pharmaceuticals (JAZZ) for Q1 2024, worth a combined $6.97B — down 2.1% from $7.12B a quarter earlier.

Sellers outnumbered buyers: 68 funds closed out of JAZZ and 54 opened new positions — a net loss of 14 holders — while 160 trimmed existing stakes and 183 added.

The largest buyer was Capital World Investors, opening a new position worth an estimated $175M. The largest seller was Wellington Management Group, cutting an estimated $128M.

  • 480 institutional investors held Jazz Pharmaceuticals (JAZZ) as of Q1 2024, down from 499 in Q4 2023.
  • Funds reported $6.97B of Jazz Pharmaceuticals stock for Q1 2024, down 2.1% quarter-over-quarter.
  • 54 funds opened new Jazz Pharmaceuticals positions in Q1 2024 and 68 closed out, a net change of -14 holders.
  • The largest Jazz Pharmaceuticals buyer in Q1 2024 was Capital World Investors, an estimated $175M added.
  • The largest Jazz Pharmaceuticals seller in Q1 2024 was Wellington Management Group, an estimated $128M sold.

Based on aggregated 13F filings for Q1 2024.